Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen E Jones

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Epilepsia|September 19, 2020
Value of 7T MRI and post-processing in patients with nonlesional 3T MRI undergoing epilepsy presurgical evaluationIrene Wang, Sehong Oh, Ingmar Blümcke, et al.
Neuroimage. Clinical|June 26, 2015
Disruption of caudate working memory activation in chronic blast-related traumatic brain injuryMary R Newsome, Sally Durgerian, Lyla Mourany, et al.
Journal of Neurosurgery|April 9, 2013
Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical articleAndrew E Sloan, Manmeet S Ahluwalia, Jose Valerio-Pascua, et al.
Clinical Breast Cancer|July 19, 2002
Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancerStephen E Jones, Gary Clark, Sherry Koleszar, et al.
Journal of Neurotrauma|September 12, 2013
Neural activation during response inhibition differentiates blast from mechanical causes of mild to moderate traumatic brain injuryBarbara L Fischer, Michael Parsons, Sally Durgerian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane studyJudith M Bliss, Lucy S Kilburn, Robert E Coleman, et al.
Lancet (London, England)|January 21, 2011
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trialCornelis J H van de Velde, Daniel Rea, Caroline Seynaeve, et al.
JAMA|February 10, 2012
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancerWillemien van de Water, Christos Markopoulos, Cornelis J H van de Velde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudyStephen E Jones, James Cantrell, Svetislava Vukelja, et al.
The Lancet. Oncology|September 7, 2013
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 studyStephen E Jones, Rufus Collea, Devchand Paul, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Epilepsia|September 19, 2020
Value of 7T MRI and post-processing in patients with nonlesional 3T MRI undergoing epilepsy presurgical evaluationIrene Wang, Sehong Oh, Ingmar Blümcke, et al.
Neuroimage. Clinical|June 26, 2015
Disruption of caudate working memory activation in chronic blast-related traumatic brain injuryMary R Newsome, Sally Durgerian, Lyla Mourany, et al.
Journal of Neurosurgery|April 9, 2013
Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical articleAndrew E Sloan, Manmeet S Ahluwalia, Jose Valerio-Pascua, et al.
Clinical Breast Cancer|July 19, 2002
Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancerStephen E Jones, Gary Clark, Sherry Koleszar, et al.
Journal of Neurotrauma|September 12, 2013
Neural activation during response inhibition differentiates blast from mechanical causes of mild to moderate traumatic brain injuryBarbara L Fischer, Michael Parsons, Sally Durgerian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane studyJudith M Bliss, Lucy S Kilburn, Robert E Coleman, et al.
Lancet (London, England)|January 21, 2011
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trialCornelis J H van de Velde, Daniel Rea, Caroline Seynaeve, et al.
JAMA|February 10, 2012
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancerWillemien van de Water, Christos Markopoulos, Cornelis J H van de Velde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudyStephen E Jones, James Cantrell, Svetislava Vukelja, et al.
The Lancet. Oncology|September 7, 2013
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 studyStephen E Jones, Rufus Collea, Devchand Paul, et al.
Pageof 13